RESVERLOGIX

TSX: RVX

Resverlogix Corp. Corporate Updates and Breakthroughs

AGM June 22, 2021

Forward Looking Statement

This presentation may contain certain forward-looking information as defined under applicable Canadian securities legislation, that are not based on historical fact, including without limitation statements containing the words "believes", "anticipates", "plans", "intends", "will", "should", "expects", "continue", "estimate", "forecasts" and other similar expressions. In particular, this presentation may include forward looking information relating to the Phase 3 BETonMACE2 clinical trial, Covid-19, vascular cognitive dementia, chronic kidney disease, fabry disease and pulmonary arterial hypertension clinical trials, and the potential role of apabetalone in the treatment of high-risk cardiovascular disease, diabetes mellitus, chronic kidney disease, end-stage renal disease treated with hemodialysis, neurodegenerative disease, Fabry disease, peripheral artery disease and other orphan diseases. Our actual results, events or developments could be materially different from those expressed or implied by these forward-looking statements. We can give no assurance that any of the events or expectations will occur or be realized. By their nature, forward-looking statements are subject to numerous assumptions and risk factors including those discussed in our Annual Information Form and most recent MD&A which are incorporated herein by reference and are available through SEDAR at www.sedar.com. The forward-looking statements contained in this news release are expressly qualified by this cautionary statement and are made as of the date hereof. The Company disclaims any intention and has no obligation or responsibility, except as required by law, to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise.

Contact
Donald McCaffrey
Email: don@resverlogix.com
Phone: 587-390-8887
Website: www.resverlogix.com

Resverlogix at a Glance

- Resverlogix Corp. is a Canadian public company developing an advanced cardiovascular drug called apabetalone. We are pioneering a technology that has the ability to turn multiple disease causing genes on or off. No actual change to the human DNA occurs. Our exciting breakthrough technology places Resverlogix as a world leader in utilizing **“epigenetics”** to regulate disease-causing genes.

- Apabetalone, was awarded **FDA Breakthrough Therapy Designation (BTD) in 2020**. This is the highest designation that a drug can receive from the FDA. BTD has only been awarded to 130 drugs previously and apabetalone is the first drug ever for mainstream cardiovascular development.

- Apabetalone’s advanced approach has been tested in over **4,200 man years of treatment** and has demonstrated its positive biological effects on patients with diseases such as;
  - Cardiovascular disease (CVD),
  - Diabetes mellitus (DM)
  - Chronic kidney disease (CKD).
  - Non-Alcoholic Fatty Liver disease (NAFLD)
  - Vascular Dementia
  - Pulmonary Arterial Hypertension
  - And very soon to be - COVID-19

Stock Symbol	TSX: RVX
Market Cap	~$220MM[1]
Shares Outstanding	241MM[1]

1. As at May 2021.

Health Canada Approves COVID-19 Trial

Health Canada / Santé Canada

Therapeutic Products Directorate
5th Floor, Holland Cross, Tower B
Address Locator # 3105A
OTTAWA, Ontario
K1A 0K9

06 April 2021

Resverlogix Corp., Canada
c/o Sue Wehner
President
Med-Script Associates Ltd.
176 Chemin St-Henri
STE-MARTHE, Quebec
J0P 1W0

Your file *Votre référence*
HC6-24-e250480
Our file *Notre référence*

No Objection Letter RE: Protocol # RVX222-CS-023 (Version 1.1)

Dear Sue Wehner:

I am pleased to inform you that the information and material to support your Clinical Trial Application for **RVX000222 (APABETALONE)**, control number **250480**, received on March 23, 2021, have been reviewed and we have no objection to your proposed study.

I would remind you of the necessity of complying with the *Food and Drug Regulations,* Division 5, in the sale of this product for clinical testing. In addition, the regulations impose record keeping responsibilities on those conducting clinical trials. You are also reminded that all clinical trials should be conducted in compliance with the Therapeutic Products Directorate's *Guideline for Good Clinical Practice.*

You are reminded of the following requirements:

As the result of very safe and promising data Health Canada has granted Resverlogix approval to conduct a **COVID-19 clinical**

Significant Apabetalone Publications – COVID-19
Dual Mechanism Approach – ACE2 reduction and Cytokine Storm

Cell

Available online 16 March 2021

In Press, Journal Pre-proof

Article

BET Inhibition Blocks Inflammation-Induced Cardiac Dysfunction and SARS-CoV-2 Infection

Richard J. Mills [1], Sean J. Humphrey [2], Patrick RJ. Fortuna [1], Mary Lor [1], Simon R. Foster [1], Gregory A. Quaife-Ryan [1], Rebecca L. Johnston [1], Troy Dumenil [1], Cameron Bishop [1], Rajeev Rurarajuu [3, 4, 5], Daniel J. Rawle [1], Thuy Le [1], Wei Zhao [5], Leo Lee [5], Charley Mackenzie-Kludas [5], Neda R. Mehdiabadi [6], Christopher Halliday [7], Dean Gilham [7] ... James E. Hudson [1]

New Results

Comment on this paper

Bromodomain and extraterminal protein inhibitor, apabetalone (RVX-208), reduces ACE2 expression and attenuates SARS-CoV-2 infection in vitro

Dean Gilham, Audrey L Smith, Li Fu, Dalia Y Moore, Abenaya Muralidharan, St. Patrick M Reid, Stephanie C Stotz, Jan O Johansson, Michael Sweeney, Norman CW Wong, Ewelina Kulikowski, Dalia El-Gamal

doi: https://doi.org/10.1101/2021.03.10.432949

Targeting transcriptional regulation of SARS-CoV-2 entry factors *ACE2* and *TMPRSS2*

Yuanyuan Qiao[a,b,c,1], Xiao-Ming Wang[a,b,1], Rahul Mannan[a,b,1], Sethuramasundaram Pitchiaya[a,b], Yuping Zhang[a,b], Jesse W. Wotring[d], Lanbo Xiao[a,b], Dan R. Robinson[a,b], Yi-Mi Wu[a,b], Jean Ching-Yi Tien[a,b], Xuhong Cao[a,b,e], Stephanie A. Simko[a,b], Ingrid J. Apel[a,b], Pushpinder Bawa[a,b], Steven Kregel[a,b], Sathiya P. Narayanan[a], Gregory Raskind[a], Stephanie J. Ellison[a], Abhijit Parolia[a,b], Sylvia Zelenka-Wang[a,b], Lisa McMurry[a,b], Fengyun Su[a], Rui Wang[a], Yunhui Cheng[a], Andrew D. Delekta[a], Zejie Mei[f], Carla D. Pretto[g], Shaomeng Wang[a,c,d,g,h], Rohit Mehra[a,b,c,2], Jonathan Z. Sexton[d,g,i,j,2], and Arul M. Chinnaiyan[a,b,c,e,k,2,3]

Number of US Deaths Due to Current Diseases in 2020

Posted on CNN - Dec. 2020 – AGM Slide



Number of US Deaths Due to Current Diseases in 2020

COVID-19 Updated to June 2021



COVID-19 CLINICAL TRIAL LAUNCH - 2021

Resverlogix' First Short Term Revenue Potential



Trial Size

100 patients

Basic Trial Design

- 4 week open label COVID-19 study for hospitalized patients
- Endpoints will be based on WHO and NIH guidelines
- Patients will have had symptoms for 7 days or less.

Clinical Cost est.

$3,000,000 USD

To be paid for by either RVX or by various Government interests under application

EVERSANA™ COMPLETE COMMERCIALIZATION

End-to-end commercial strategy, operational excellence and a success share delivery model:

- ✓ Minimize financial exposure
- ✓ Keep revenues
- ✓ Maintain full ownership

Adding more strength for clients every day




Lead Program Also Advancing

FDA Approves Breakthrough Therapy Designation

"A breakthrough therapy designation is for a drug that treats a serious or life-threatening condition and preliminary clinical evidence indicates that the drug may demonstrate substantial improvement on a clinically significant endpoint(s) over available therapies."
FDA Website



U.S. FOOD & DRUG ADMINISTRATION

IND 76487

GRANT –
BREAKTHROUGH THERAPY DESIGNATION

Resverlogix Corp.
Attention: Barry Calvarese
Consultant, Regulatory Affairs
44 Montgomery Street, Suite 4010
San Francisco, CA 94104

Dear Mr. Calvarese:

Please refer to your investigational new drug application (IND) submitted under section 505(i) of the Federal Food, Drug, and Cosmetic Act for apabetalone (RVX000222).

We also refer to your December 4, 2019, request for Breakthrough Therapy designation. We have reviewed your request and have determined that apabetalone, in

As the result of very safe and promising data the FDA granted Resverlogix the coveted **Breakthrough Therapy Designation**

Efficacy - The Drug Works! Trials confirmed a highly significant reduction in Death, Heart Attacks and CHF



No. at Risk					No. of Events
Placebo	264	244	151	36	42
Apabetalone	265	253	169	41	15

- The effect of the co-administration of apabetalone and SGLT2 or DPP4 inhibitors – quantified by CV death, non-fatal MI, stroke and hospitalization for congestive heart failure (CHF) – illustrated a significant reduction of events compared to placebo and SGLT2 or DPP4 inhibitors
  - HR = 0.37 (95% CI, 0.22–0.62; p=0.0002)
- Apabetalone was well tolerated with similar rates of adverse events compared to placebo

Top standard of care includes: high intensity statins, ACE inhibitors/angiotensin II blockers, beta blockers, antiplatelet agents

RVX Internal Analysis January 2020

Apabetalone treatment led to a significant 63% hazard reduction of MACE and hospitalization for Congestive Heart Failure (CHF) compared to placebo in patients receiving SGLT2 or DPP4 Inhibitors

Kaplan-Meier Estimates by CKD/Non-CKD for MACE Apabetalone Compared to Placebo



CKD Group (eGFR<60)

Placebo Events - 35/164 (21.3%)

Apabetalone Events - 13/124 (10.5%)

Hazard Ratio = 0.50 [95%CIs: 0.26,0.96; **p=0.03**]

Source: Kalantar-Zadeh et al 2020; Apabetalone in CKD and MACE; publication pending

Apabetalone treatment led to a significant 50% hazard reduction of MACE compared to placebo in patients with CKD

TARGETED - GLOBAL DEVELOPMENT PLAN

Planning details between Resverlogix and various potential partners



Trial Size

3,600 patients

Basic Trial Design

- Type 2 Diabetes patients post ACS 7-180 days
- Estimated glomerular filtration rate (eGFR) between 20 and 60 mL/min/1.73 m^2
- SGLT2 inhibitor if clinically indicated mandated for all subjects
- Endpoint, time to the first occurrence of narrowly defined MACE (CV death and MI) or hospital admission for CHF

Clinical Cost est.

$60-70,000,000 USD

To be paid for by the Pharma side in a partnership agreement

Resverlogix 12 Month Key Milestones



June
FDA confirms key aspects of BETonMACE2 registration enabling study

June
BETonMACE CKD subgroups results presented at ERA-EDTA

October
12MM USD conversion of debenture; Entered into $10MM USD definitive stock purchase agreement

August
$2MM USD private placement

November
Filing of new IP for apabetalone in combination with oral anti-diabetic therapies

October
Publication focused on apabetalone's potential for COVID-19

April
Health Canada approved apabetalone for a COVID-19 trial

March
CELL Journal published Resverlogix COVID-19 data

April
American Society of Nephrology published very positive kidney data regarding apabetalone

April
Biomedicines Journal published positive UNMC data regarding apabetalone and COVID-19 in lung cells

June
Critical Eversana deal announced

May
Resverlogix closes over $12MM CAD in financing including $6MM USD from Hepalink